Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437c
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
This is a multicenter, open, single arm dose escalation and dose expansion clinical study to
evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of FCN-437c alone
or in combination with letrozole in women with ER +/ HER2 - advanced breast cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Ahon Pharmaceutical Co., Ltd.
Collaborators:
Fudan University Sir Run Run Shaw Hospital Zhejiang Cancer Hospital